This subproject is one of many research subprojects utilizing theresources provided by a Center grant funded by NIH/NCRR. The subproject andinvestigator (PI) may have received primary funding from another NIH source,and thus could be represented in other CRISP entries. The institution listed isfor the Center, which is not necessarily the institution for the investigator.The objective of this study is to systematically follow men diagnosed with protstate cancer detected through Dr. Catalona's PSA screening study conducted at Washington University from 1989 to 2001. This follow-up study provides a unique opportunity to study the long-term outcomes of early detection of prostate cancer in the screening population treated with a variety of methods. Outcomes include cancer recurrence or progression rates, cancer-specific survival rates, mortality rates and quality of life outcomes. To date, 3274 men with screen-detected prostate cancer have been enrolled in this study. Enrollment for this study is open-ended to the extent that men with newly diagnosed prostate cancer are continually added from the PSA screening program that was closed on 11/14/01. Preliminary observations indicate that in the study cohort, about 67% undergo radical prostatectomy as primary treatment, 15% have radiation therapy, 6% have hormonal therapy, and 1% have cryoablation, and 11% are conservatively managed. In recent years, a greater proportion of patients have been treated with brachytherapy. More follow-up time is needed to study the cancer recurrence or progression rates, mortality, and dynamic changes in quality of life in this cohort.
Showing the most recent 10 out of 497 publications
